Aripiprazole Tablet
NDC 46708-258
Product Information
Aripiprazole is a ANDA-approved product labeled by Alembic Pharmaceuticals Limited. Aripiprazole is used to treat certain mental/mood disorders (such as bipolar disorder, schizophrenia, Tourette's syndrome, and irritability associated with autistic disorder). It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 46708-258 and 5 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
PINK (C48328 - LIGHT PINK)
WHITE (C48325 - WHITE TO OFF-WHITE)
ROUND (C48348)
7 MM
251
250
252
253
L254
Code Structure Chart
Product Details
What is NDC 46708-258?
What are the uses of this product?
What are Active Ingredients of this product?
- ARIPIPRAZOLE 20 mg/1 - A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ARIPIPRAZOLE (UNII: 82VFR53I78)
- ARIPIPRAZOLE (UNII: 82VFR53I78) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)
- STARCH, CORN (UNII: O8232NY3SJ)
- CROSPOVIDONE (UNII: 68401960MK)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 349490 - ARIPiprazole 15 MG Oral Tablet
- RxCUI: 349490 - aripiprazole 15 MG Oral Tablet
- RxCUI: 349545 - ARIPiprazole 10 MG Oral Tablet
- RxCUI: 349545 - aripiprazole 10 MG Oral Tablet
- RxCUI: 349547 - ARIPiprazole 30 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Aripiprazole
Aripiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of age and older. It is also used alone or with other medications to treat episodes of mania or mixed episodes (symptoms of mania and depression that happen together) in adults, teenagers, and children 10 years of age and older with bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is also used with an antidepressant to treat depression when symptoms cannot be controlled by the antidepressant alone. Aripiprazole is also used to treat children 6 to 17 years of age who have autistic disorder (a developmental problem that causes difficulty communicating and interacting with others). Aripiprazole may help control irritable behavior such as aggression, temper tantrums, and frequent mood changes in these children. Aripiprazole is also used to treat children 6 to 18 years of age who have Tourette's disorder (a condition characterized by the need to perform repeated motions or to repeat sounds or words). Aripiprazole is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
[Learn More]
* Please review the full disclaimer at the bottom of this page.